Response to Igarashi, et al, cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan

Expert Rev Vaccines. 2022 May;21(5):589-590. doi: 10.1080/14760584.2022.2036127. Epub 2022 Feb 16.

Authors

Kristen A Feemster¹, Youngju Kim², Machiko Abe², Kelly Johnson³, Shin Sasaki²

Affiliations

¹ Global Medical and Scientific Affairs, Merck & Co., Inc., Kenilworth, NJ, USA.
² Medical Affairs- Vaccines, Merck Sharp & Dohme Corp. K.K., Tokyo, Japan.
³ Center for Observational and Real-World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.

PMID: 35172667
DOI: 10.1080/14760584.2022.2036127

No abstract available

Keywords: Pneumococcal; immunity; vaccine.

Publication types

Research Support, Non-U.S. Gov't
Letter

MeSH terms

Adult
Cost-Benefit Analysis
Humans
Japan / epidemiology
Pneumococcal Infections* / epidemiology
Pneumococcal Infections* / prevention & control
Streptococcus pneumoniae